Hsi ED, et al. - Given that serum soluble chemokines/cytokines produced by Hodgkin-cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL), researchers evaluated serum TARC, MDC, IL10, and soluble CD163 (sCD163) levels in cHL patients treated on S0816, an intergroup phase 2 response-adapted study assessing escalated therapy for interim PET (positron emission tomography)(PET2)-positive patients. The levels were assessed at baseline, time of interim fluorodeoxyglucose (FDG)-PET, and post-therapy. Findings revealed a correlation between serum cytokine levels and outcome in cHL. They observed a correlation of Epstein-Barr virus (EBV)-positivity with higher sCD163 and IL10 levels but lower TARC levels. Favorable progression free survival (PFS) was observed in relation to sCD163 levels at the time of PET2, adjusting for PET2 status. In univariable analysis, the correlation of post-therapy TARC, MDC, and IL10 with PFS and overall survival (OS) was observed, which remained significant adjusting for international prognostic score.